Guardian Pharmacy Services, Inc. (NYSE:GRDN) Stock Has Consensus Target Price of $43.83

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $45.57.

A number of equities analysts have weighed in on the stock. Oppenheimer upped their price objective on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Weiss Ratings upgraded Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 20th. Wall Street Zen lowered Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research report on Saturday, September 19th. KeyCorp assumed coverage on shares of Guardian Pharmacy Services in a research report on Tuesday. They set an “overweight” rating and a $52.00 price target for the company. Finally, Bank of America lifted their price target on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th.

Institutional Investors Weigh In On Guardian Pharmacy Services

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jennison Associates LLC boosted its position in Guardian Pharmacy Services by 609.5% during the first quarter. Jennison Associates LLC now owns 822,784 shares of the company’s stock valued at $30,986,000 after purchasing an additional 706,823 shares during the last quarter. Braun Stacey Associates Inc. acquired a new stake in Guardian Pharmacy Services in the second quarter valued at approximately $14,234,000. Ranger Investment Management L.P. bought a new stake in Guardian Pharmacy Services in the second quarter worth approximately $7,263,000. Dimensional Fund Advisors LP grew its position in Guardian Pharmacy Services by 200.0% in the first quarter. Dimensional Fund Advisors LP now owns 208,594 shares of the company’s stock worth $7,855,000 after acquiring an additional 139,070 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of Guardian Pharmacy Services by 40.5% during the 1st quarter. Sei Investments Co. now owns 358,181 shares of the company’s stock worth $13,489,000 after purchasing an additional 103,177 shares during the last quarter.

Key Headlines Impacting Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: KeyCorp’s new coverage establishes a bullish outlook for Guardian Pharmacy Services, with analyst Z. Haggerty projecting EPS of $1.16 for fiscal 2026, $1.27 for fiscal 2027 and $1.46 for fiscal 2028. The estimates suggest continued earnings growth and provide a fundamental basis for the $52 target. Guardian Pharmacy Services Stock Rated Overweight in New Coverage at KeyCorp
• Positive Sentiment: KeyCorp’s quarterly projections call for EPS of $0.27 in Q3 2026, $0.36 in Q4 2026 and $0.28, $0.28, $0.30 and $0.40 in the four quarters of 2027. The rising quarterly outlook, particularly toward late 2027, reinforces expectations for operating and earnings momentum.
• Neutral Sentiment: KeyCorp’s fiscal 2026 EPS estimate of $1.16 is slightly below the broader consensus estimate of $1.19, which could temper enthusiasm in the near term. However, its longer-term estimates point to acceleration in 2027 and 2028. KeyBanc initiates coverage of Guardian Pharmacy Services at overweight

Guardian Pharmacy Services Price Performance

NYSE:GRDN opened at $41.25 on Monday. The business’s 50-day moving average is $40.77 and its two-hundred day moving average is $39.21. Guardian Pharmacy Services has a 12 month low of $23.14 and a 12 month high of $48.33. The firm has a market capitalization of $2.05 billion, a PE ratio of 40.05, a price-to-earnings-growth ratio of 2.18 and a beta of 0.06.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.26 by $0.03. The firm had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. Equities analysts anticipate that Guardian Pharmacy Services will post 1.18 EPS for the current year.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc is a long-term care pharmacy company that provides prescription medications and related pharmacy services to residents of assisted living communities, skilled nursing facilities, memory care centers and other institutional care settings.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, pharmacy consulting and clinical support. Guardian works with care providers, residents and their families to help coordinate medication regimens, improve adherence and support the ongoing pharmacy needs of patients who may require complex or recurring treatments.

Guardian Pharmacy Services operates through a network of community-based pharmacies serving long-term care customers in multiple U.S.